In the fall, Heap's customers can pick sunflowers, mums and pumpkins; bump along on hayrides; and wander through a corn maze. The farm also produces commodity corn and soy, often for international ...
Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a phase 2 trial. The Bay Area-based biotech unveiled its ambition earlier ...
In the fall, Heap's customers can pick sunflowers, mums and pumpkins; bump along on hayrides; and wander through a corn maze. The farm also produces commodity corn and soy, often for international ...
Obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics have met their IPO expectations as the two companies prepare to join the Nasdaq this morning. While Metsera is offering ...
Maze seeks as much as $133 mln in New York IPO Backers include Alphabet's GV and Third Rock Ventures Biotech IPOs set for ramp up in coming weeks Jan 27 (Reuters) - Drug developer Maze ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback